Monoklonale Gammopathie unklarer Signifikanz bei rheumatologischen Erkrankungen

Zusammenfassung

In der rheumatologischen Praxis wird eine monoklonale Gammopathie (MGUS) häufig als Zufallsbefund entdeckt. Meist handelt es sich um einen Laborbefund ohne Krankheitswert, diese Fälle werden als monoklonale Gammopathien unklarer Signifikanz (MGUS) bezeichnet. Für mehrere rheumatisch-entzündliche Systemerkrankungen ist ein erhöhtes Risiko für MGUS bekannt. Aus einer MGUS kann sich ein multiples Myelom, eine primär systemische Amyloidose oder eine andere lymphatische Neoplasie entwickeln. Die relevanten Krankheitsdefinitionen werden genannt und es werden Algorithmen aufgezeigt, um eine monoklonale Gammopathie weiter abzuklären und abhängig vom Progressionsrisiko Verlaufskontrollen vorzunehmen. Die Erkenntnisse darüber, ob rheumatologische Therapien Einfluss auf das Progressionsrisiko haben, sind bislang begrenzt.

Abstract

In rheumatology practice, monoclonal gammopathy of undetermined significance is a common incidental finding. Most often, gammopathies are benign in nature and lack associated symptoms. For this phenomenon, the term “monoclonal gammopathy of undetermined significance (MGUS)” has been coined. Several rheumatic inflammatory diseases are known to be associated with an elevated risk of MGUS. MGUSs may evolve into multiple myeloma, systemic light-chain amyloidosis or other lymphatic malignancies. This article provides relevant definitions of disease entities and highlights algorithms for further diagnostic work-up and follow-up for monoclonal gammopathy.

Schlüsselwörter

Monoklonale Gammopathie unklarer Signifikanz - rheumatoide Arthritis - Sjögren-Syndrom - Basistherapie

Key words

monoclonal gammopathy of undetermined significance - rheumatoid, arthritis - Sjögren’s syndrome - disease-modifying antirheumatic drugs

Publication History

Article published online:
22 October 2020

• Literatur

• 1 Ghobrial IM, Detappe A, Anderson KC. et al. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol 2018; 15: 219-233
• 2 Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance. Blood 2019; 133: 2484-2494
• 3 Kortüm Martin, Einsele Hermann, Naumann Ralph. et al. Hartmut Goldschmidt. Monoklonale Gammopathie unklarer Signifikanz. Leitlinie. Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen. www.onkopedia.de;Stand: August 2010
• 4 Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma. Working Group. Br J of Haemat 2003; 121: 749-757
• 5 Mateos MV, Hernández MT, Giraldo P. et al. Lenalidomide Plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. N Engl J Med 2013; 369: 438-447
• 6 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-e548
• 7 Goldenberg GJ, Paraskevas F, Israels LG. The association of rheumatoid arthritis with plasma cell neoplasm. Arthritis Rheum 1969; 12: 569-579
• 8 Ali YM, Urowitz MB, Ibanez D. et al. Monoclonal gammopathy in systemic lupus erythematosus. Lupus 2007; 16: 426-429
• 9 Tomi AL, Belkhir R, Nocturne G. et al. Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome. Arthritis Rheumatol 2016; 68: 1245-1250
• 10 Brito-Zerón P, Retamozo S, Gandía M. et al. Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 2012; 39: 43-48
• 11 McShane CM, Murray LJ, Landgren O. et al. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol Biomarkers Prev 2014; 23: 332-342
• 12 Lindqvist EK, Landgren O, Lund SH. et al. History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. Ann Hematol 2017; 96: 261-269
• 13 Tsimberidou AM, Waddelow T, Kantarjian HM. et al. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res 2003; 27: 375-380
• 14 Prignano F, Pescitelli L. et al. Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment. J Eur Acad Dermatol Venereol 2012; 26: 1444-1448
• 15 Conti A, Esposito I, Lasagni C. et al. Monoclonal gammopathy of undetermined significance in patients with psoriasis: is it really a side effect of biological therapy?. Drug Dev Res 2014; 75 (Suppl. 01) 35-37
• 16 Di Lernia V, Ficarelli E, Lallas A. et al. Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study. J Eur Acad Dermatol Venereol 2015; 29: 2262-2263
• 17 Salliot C, Beaudoin C, Chauffier K. et al. Prevalence and Evolution of Monoclonal Gammopathy of Undetermined Significance in Patients with Rheumatoid Arthritis Treated with Aabatacept: Data from the ORA Registry. Ann Rheum Dis 2015; 74 (Suppl. 12) 445
• 18 Néel A, Henry B, Barbarot S. et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome: a French multicenter study. Autoimmun Rev 2014; 13: 1035-1041
• 19 de Koning HD, Bodar EJ, van der Meer JW. et al. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37: 137
• 20 Matsuyama Y, Nagashima T. et al. Successful Treatment of a Patient with Rheumatoid Arthritis and IgA-Kappa Multiple Myeloma with Tocilizumab. Intern Med 2011; 50: 639-642
• 21 Kapoor P, Greipp PT, Morice WG. et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology 2008; 141: 135-148